Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood (2011) 118 (21): 1412.

https://doi.org/10.1182/blood.V118.21.1412.1412

Published: 2011

Journal Articles

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Blood (2010) 116 (21): 307.

https://doi.org/10.1182/blood.V116.21.307.307

Published: 2010

Journal Articles

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez, Ma Teresa Cibeira, Raquel de Paz, Ma José Terol, José García-Laraña, Enrique Bengoechea, Rafael Martínez, Alejandro Martin, Felipe de Arriba, Luis Palomera, José Hernández, Jose-Luis Bello, María-Luisa Martín, Yolanda González, Joan Blade, MD, Juan José Lahuerta, J.F San Miguel, MD, PhD

Blood (2008) 112 (11): 651.

https://doi.org/10.1182/blood.V112.11.651.651

Published: 2008

Journal Articles

Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study

Blood (2008) 112 (11): 161.

https://doi.org/10.1182/blood.V112.11.161.161

Published: 2008

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

Journal Articles

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Blood (2006) 108 (7): 2165–2172.

https://doi.org/10.1182/blood-2006-04-019778

Published: 2006

Journal Articles

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

Blood (2006) 108 (2): 662–668.

https://doi.org/10.1182/blood-2005-12-5125

Published: 2006

Includes: Supplemental data

Journal Articles

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Blood (2005) 106 (12): 3755–3759.

https://doi.org/10.1182/blood-2005-03-1301

Published: 2005

Journal Articles

Apoptotic and Multi-Drug Resistance Profile in Elderly AML Patients.

Maria-Belen Vidriales, MD, PhD, Lilia Suarez, José García-Laraña, MD, PhD, Antonio López, María José Moreno, MD, PhD, Rafael Martinez, MD, PhD, Mar Tormo, MD, Esperanza Lavilla, MD, Consuelo López-Berges, MD, PhD, María de Santiago, Jesús F. San Miguel, MD, PhD, Alberto Orfao, MD, PhD, for the Pethema Cooperative Group

Blood (2004) 104 (11): 4472.

https://doi.org/10.1182/blood.V104.11.4472.4472

Published: 2004

NARROW

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Apoptotic and Multi-Drug Resistance Profile in Elderly AML Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only